Clinical Trial Search

Primary: Mean Intraocular Pressure (IOP) at Week 2, Week 6, and Month 3 for Each Assessment Time Point (8 AM, 10 AM, and 4 PM) — 19.4; 19.5; 18.6; 18.6 millimeters mercury (mmHg)

Primary: Average Change From Baseline to Month 1 Through Month 3 on Visual Acuity of the Study Eye — 55.4; 55.8; 54.7; 66.0 Letters

Primary: Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study. — 1.13; 0.92 g/dL

Primary: HbA1c Change From Baseline to Week 12 — -0.11; -0.53 Percent — p=<0.0001

Primary: Change From Week 2 to Week 6 in Composite Score of Patient Satisfaction With Injection Experience — 4.1; 4.8; 0.7 units on a scale — p=<0.0001

Primary: Efficacy Endpoint: The Percent of Patients Off Class I or III Antiarrhythmic Drugs and Out of AF as Determined by 24 Hour Holter Recording at 9 Months — 42.6 percentage…

Primary: Decrease in Preoperative P-PTH — -2.2; 0.2 pmol/l

Primary: Efficacy Endpoint: The Percent of Patients Off Class I and/or III Antiarrhythmic Drugs and Out of Atrial Fibrillation as Determined by 24 Hour Holter Recording Conducted…

Primary: Overall Survival — 6.7; 5.2 months

Primary: Adjusted Mean Change in HbA1c Levels — -0.58; -0.63; -0.82; -0.13 Percent — p=<0.0001

Primary: Haemagglutination Inhibition (HI) Antibody Titers, Against Each of the Vaccine Influenza Virus Strains. — 84.03; 40.48; 306.51; 159.02 Titer

Primary: Adjusted Mean Change in HbA1c Levels — 0.04; -0.45 Percent — p=<0.0001

Primary: Learning and Memory Measures. — -3.38; -.07; -1.38; 1.93 Items recalled — p== .19

Primary: Kaplan-Meier Estimates of Overall Survival (All Randomized Participants) — 98.9; 97.7; 96.0; 93.6 Percentage of participants

Primary: Adjusted Mean Change in Total Body Weight — -0.88; -2.96 kg — p=<0.0001